Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Effector Therapeutics Inc (EFTR)

Effector Therapeutics Inc (EFTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,338
  • Shares Outstanding, K 41,893
  • Annual Sales, $ 1,430 K
  • Annual Income, $ 15,800 K
  • 60-Month Beta 0.31
  • Price/Sales 11.53
  • Price/Cash Flow 1.00
  • Price/Book 1.41
Trade EFTR with:
  • Price/Earnings ttm 3.58
  • Earnings Per Share ttm 0.11
  • Most Recent Earnings -0.23 on 11/07/22
  • Next Earnings Date 11/14/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 80.44%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 639.52% on 08/09/22
  • IV Low 0.00% on 12/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 456
  • Open Int (30-Day) 456

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year 0.44
  • Growth Rate Est. (year over year) -156.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3800 +10.74%
on 12/09/22
0.5900 -28.68%
on 11/14/22
-0.0891 (-17.47%)
since 11/09/22
3-Month
0.3800 +10.74%
on 12/09/22
0.6970 -39.63%
on 10/11/22
-0.2241 (-34.75%)
since 09/09/22
52-Week
0.3800 +10.74%
on 12/09/22
9.5400 -95.59%
on 12/27/21
-6.2992 (-93.74%)
since 12/09/21

Most Recent Stories

More News
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of...

EFTR : 0.4208 (+7.90%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 1.1600 (+5.45%)
ANGN : 0.8321 (+0.25%)
CKPT : 3.72 (+0.27%)
EFTR : 0.4208 (+7.90%)
FRLN : 0.5525 (-6.36%)
GLYC : 2.07 (-11.91%)
MGNX : 6.24 (+0.32%)
OCUP : 3.08 (unch)
PHAS : 0.0701 (-26.21%)
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO and REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics Announces Transition in Clinical Leadership

Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity Robert Sikorski, M.D., Ph.D., to take on expanded role...

EFTR : 0.4208 (+7.90%)
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of...

EFTR : 0.4208 (+7.90%)
eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective...

EFTR : 0.4208 (+7.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.4839
2nd Resistance Point 0.4549
1st Resistance Point 0.4379
Last Price 0.4208
1st Support Level 0.3919
2nd Support Level 0.3629
3rd Support Level 0.3459

See More

52-Week High 9.5400
Fibonacci 61.8% 6.0409
Fibonacci 50% 4.9600
Fibonacci 38.2% 3.8791
Last Price 0.4208
52-Week Low 0.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar